Two Bristol-Myers Squibb drugs approved by Scottish Medicines Consortium
The Scottish Medicines Consortium has approved two new treatments, one for skin cancer and one for hepatitis C.
Daklinza (daclatasvir), manufactured by Bristol-Myers Squibb (NYSE: BMY), has been accepted by the SMC for adult patients with chronic hepatitis C with significant fibrosis or compensated cirrhosis, both of which represent significant liver damage.
It is used in combination with other agents, including sofosbuvir, to treat patients with hepatitis C genotypes 1, 3 and 4, which represents more than 94% of cases in Scotland. This will allow eligible patients in Scotland to have access to a potentially curative oral treatment regimen that does not contain interferon, which is a standard of care commonly associated with adverse events such as flu-life symptoms.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze